Physician

Mark Abdelmalek, M.D.

According to 2025 Medicare claims, Mark Abdelmalek, M.D. (NPI: 1972543155) practices micrographic dermatologic surgery in the Camden, NJ market, with the plurality of this provider's patient population coming from Burlington, NJ. This provider's primary affiliated billing organization is DERMATOLOGY OF PHILADELPHIA / MOHS SURGERY CENTER, LLC (NPI: 1932740461; TIN: 475167867) and primary practice location at 08043-4502.

Abdelmalek's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 588 traditional Medicare patients, billed 2,707 HCPCS/CPT codes, and received $537,971 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 746 prescription claims across 406 beneficiaries totaling $13,731 in drug costs, led by Clobetasol Propionate (Clobetasol Propionate). Open Payments data shows 2 records totaling $28. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $124,703 to $537,971. Similarly, Part D prescription costs have risen steadily, from $703 to $13,731. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	149	786	$124,703
2016	176	867	$113,656
2017	222	962	$119,402
2018	250	1,234	$158,621
2019	280	1,598	$243,603
2020	297	1,289	$259,224
2021	422	2,273	$414,182
2022	392	3,192	$426,433
2023	534	2,741	$463,760
2024	588	2,707	$537,971

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	22	29	$703
2016	17	28	$1,411
2017	17	40	$2,574
2018	133	277	$8,573
2019	183	467	$22,442
2020	197	455	$16,057
2021	296	643	$17,765
2022	283	606	$21,035
2023	381	711	$20,338
2024	406	746	$13,731

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17311	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks	313	375	$489
17312	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks	108	141	$348
11102	Biopsy of related skin growth, first growth	120	141	$71
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	160	213	$62
17000	Destruction of precancer skin growth, 1 growth	90	125	$40

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Clobetasol Propionate	Clobetasol Propionate	32	900	$1,760
Mupirocin	Mupirocin	133	2,706	$890
Cefadroxil	Cefadroxil	120	860	$770
Triamcinolone Acetonide	Triamcinolone Acetonide	77	2,580	$666
Cephalexin	Cephalexin	57	420	$646

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$28	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Abdelmalek, M.D.?

Tedicare shows public-source Medicare data for Mark Abdelmalek, M.D. (NPI 1972543155), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Abdelmalek, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Abdelmalek, M.D.?

Mark Abdelmalek, M.D. is linked to DERMATOLOGY OF PHILADELPHIA / MOHS SURGERY CENTER, LLC (billing NPI 1932740461) in the available physician profile data.

Does Mark Abdelmalek, M.D. have Open Payments data?

Mark Abdelmalek, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.